{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:37:40Z","timestamp":1785465460979,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"This study was funded by Multicenter clinical big data study and multi-path tumorigenesis mechanisms and precision treatment research on brainstem glioma","award":["JINGYIYAN2018-7"],"award-info":[{"award-number":["JINGYIYAN2018-7"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s11060-023-04323-5","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:03:05Z","timestamp":1683093785000},"page":"159-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A novel CDK4\/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma"],"prefix":"10.1007","volume":"163","author":[{"given":"Pengcheng","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tantan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"4323_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fonc.2015.00237","volume":"5","author":"MI Vanan","year":"2015","unstructured":"Vanan MI, Eisenstat DD (2015) DIPG in children\u2014what can we learn from the past? Front Oncol 5:237. https:\/\/doi.org\/10.3389\/fonc.2015.00237","journal-title":"Front Oncol"},{"key":"4323_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drup.2019.06.001","volume":"44","author":"MH Meel","year":"2019","unstructured":"Meel MH, Kaspers GJL, Hulleman E (2019) Preclinical therapeutic targets in diffuse midline glioma. Drug Resist Updates 44:15\u201325. https:\/\/doi.org\/10.1016\/j.drup.2019.06.001","journal-title":"Drug Resist Updates"},{"key":"4323_CR3","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1128\/mcb.21.14.4773-4784.2001","volume":"21","author":"SA Ezhevsky","year":"2001","unstructured":"Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF (2001) Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21:4773\u20134784. https:\/\/doi.org\/10.1128\/mcb.21.14.4773-4784.2001","journal-title":"Mol Cell Biol"},{"key":"4323_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ (2017) CDK4\/6 inhibition triggers anti-tumour immunity. Nature 548:471\u2013475. https:\/\/doi.org\/10.1038\/nature23465","journal-title":"Nature"},{"key":"4323_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, von Bueren AO, Baudis M, Resnick A, Jones C (2017) Integrated molecular meta-analysis of 1000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32:520-537e525. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017","journal-title":"Cancer Cell"},{"key":"4323_CR6","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.2147\/cmar.S167095","volume":"10","author":"DJ Asby","year":"2018","unstructured":"Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WG, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS (2018) Combined use of CDK4\/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. Cancer Manage Res 10:3483\u20133500. https:\/\/doi.org\/10.2147\/cmar.S167095","journal-title":"Cancer Manage Res"},{"key":"4323_CR7","doi-asserted-by":"publisher","first-page":"e77639","DOI":"10.1371\/journal.pone.0077639","volume":"8","author":"KL Barton","year":"2013","unstructured":"Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M, Kirsch DG, Becher OJ (2013) PD-0332991, a CDK4\/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS ONE 8:e77639. https:\/\/doi.org\/10.1371\/journal.pone.0077639","journal-title":"PLoS ONE"},{"key":"4323_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ebiom.2019.06.025","volume":"45","author":"Y Sun","year":"2019","unstructured":"Sun Y, Sun Y, Zhang L, Xi Q (2019) Authors\u2019 reply to \u201cTranslating palbociclib to the clinic for DIPG\u2014what is truly achievable?\u201d EBioMedicine 45:23\u201324. https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.025","journal-title":"EBioMedicine"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ebiom.2019.04.043","volume":"43","author":"Y Sun","year":"2019","unstructured":"Sun Y, Sun Y, Yan K, Li Z, Xu C, Geng Y, Pan C, Chen X, Zhang L, Xi Q (2019) Potent anti-tumor efficacy of palbociclib in treatment-na\u00efve H3.3K27M-mutant diffuse intrinsic pontine glioma. EBioMedicine 43:171\u2013179. https:\/\/doi.org\/10.1016\/j.ebiom.2019.04.043","journal-title":"EBioMedicine"},{"key":"4323_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427\u20131438","journal-title":"Mol Cancer Ther"},{"key":"4323_CR11","doi-asserted-by":"publisher","first-page":"e0118926","DOI":"10.1371\/journal.pone.0118926","volume":"10","author":"KG Halvorson","year":"2015","unstructured":"Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, Crabtree DM, Cordero FJ, Singh R, Spasojevic I, Berlow N, Pal R, Becher OJ (2015) A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. PLoS ONE 10:e0118926. https:\/\/doi.org\/10.1371\/journal.pone.0118926","journal-title":"PLoS ONE"},{"key":"4323_CR12","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1158\/1078-0432.Ccr-18-0924","volume":"24","author":"MH Meel","year":"2018","unstructured":"Meel MH, de Gooijer MC, Guill\u00e9n Navarro M, Waranecki P, Breur M, Buil LCM, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero Carcaboso A, Bugiani M, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E (2018) MELK inhibition in diffuse intrinsic pontine glioma. Clin Cancer Res 24:5645\u20135657. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0924","journal-title":"Clin Cancer Res"},{"key":"4323_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fonc.2018.00239","volume":"8","author":"KE Warren","year":"2018","unstructured":"Warren KE (2018) Beyond the blood: brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front Oncol 8:239. https:\/\/doi.org\/10.3389\/fonc.2018.00239","journal-title":"Front Oncol"},{"key":"4323_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1535-7163.Mct-15-0093","volume":"15","author":"RK Mittapalli","year":"2016","unstructured":"Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G, Elmquist WF, Becher OJ (2016) ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B-driven brainstem glioma model. Mol Cancer Ther 15:819\u2013829. https:\/\/doi.org\/10.1158\/1535-7163.Mct-15-0093","journal-title":"Mol Cancer Ther"},{"key":"4323_CR15","doi-asserted-by":"publisher","first-page":"e61512","DOI":"10.1371\/journal.pone.0061512","volume":"8","author":"SJ Veringa","year":"2013","unstructured":"Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E (2013) In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS ONE 8:e61512. https:\/\/doi.org\/10.1371\/journal.pone.0061512","journal-title":"PLoS ONE"},{"key":"4323_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-015-0379-9","volume":"75","author":"S Dhillon","year":"2015","unstructured":"Dhillon S (2015) Palbociclib: first global approval. Drugs 75:543\u2013551. https:\/\/doi.org\/10.1007\/s40265-015-0379-9","journal-title":"Drugs"},{"key":"4323_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/ije\/23.3.458","volume":"23","author":"CA Stiller","year":"1994","unstructured":"Stiller CA, Nectoux J (1994) International incidence of childhood brain and spinal tumours. Int J Epidemiol 23:458\u2013464. https:\/\/doi.org\/10.1093\/ije\/23.3.458","journal-title":"Int J Epidemiol"},{"key":"4323_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1470-2045(06)70615-5","volume":"7","author":"D Hargrave","year":"2006","unstructured":"Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241\u2013248. https:\/\/doi.org\/10.1016\/s1470-2045(06)70615-5","journal-title":"Lancet Oncol"},{"key":"4323_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10555-019-09824-2","volume":"38","author":"WM Rashed","year":"2019","unstructured":"Rashed WM, Maher E, Adel M, Saber O, Zaghloul MS (2019) Pediatric diffuse intrinsic pontine glioma: where do we stand? Cancer Metastasis Rev 38:759\u2013770. https:\/\/doi.org\/10.1007\/s10555-019-09824-2","journal-title":"Cancer Metastasis Rev"},{"key":"4323_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s0140-6736(67)91485-7","volume":"1","author":"LP Lassman","year":"1967","unstructured":"Lassman LP, Arjona VE (1967) Pontine gliomas of childhood. Lancet 1:913\u2013915. https:\/\/doi.org\/10.1016\/s0140-6736(67)91485-7","journal-title":"Lancet"},{"key":"4323_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2017.10.013","volume":"120","author":"HS Gwak","year":"2017","unstructured":"Gwak HS, Park HJ (2017) Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol\/Hematol 120:111\u2013119. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.10.013","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4323_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41419-020-02800-7","volume":"11","author":"M Wiese","year":"2020","unstructured":"Wiese M, Hamdan FH, Kubiak K, Diederichs C, Gielen GH, Nussbaumer G, Carcaboso AM, Hulleman E, Johnsen SA, Kramm CM (2020) Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Cell Death Dis 11:673. https:\/\/doi.org\/10.1038\/s41419-020-02800-7","journal-title":"Cell Death Dis"},{"key":"4323_CR23","doi-asserted-by":"publisher","first-page":"108994","DOI":"10.1016\/j.celrep.2021.108994","volume":"35","author":"A Ehteda","year":"2021","unstructured":"Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C, Tang Y, Khan A, Ung C, Tolhurst O, Kankean A, Hayden E, Lehmann R, Shen S, Gopalakrishnan A, Trebilcock P, Gurova K, Gudkov AV, Norris MD, Haber M, Vittorio O, Tsoli M, Ziegler DS (2021) Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep 35:108994. https:\/\/doi.org\/10.1016\/j.celrep.2021.108994","journal-title":"Cell Rep"},{"key":"4323_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1158\/2159-8290.Cd-20-1201","volume":"12","author":"DM Carvalho","year":"2022","unstructured":"Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, Corley EA, Smith DP, Ruddle R, Donovan A, Pal A, Raynaud FI, Temelso S, Mackay A, Overington JP, Phelan A, Sheppard D, Mackinnon A, Zebian B, Al-Sarraj S, Merve A, Pryce J, Grill J, Hubank M, Cruz O, La Morales A, Mueller S, Carcaboso AM, Carceller F, Jones C (2022) Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov 12:416\u2013431. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1201","journal-title":"Cancer Discov"},{"key":"4323_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","volume":"36","author":"JN Anastas","year":"2019","unstructured":"Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y (2019) Re-programing chromatin with a bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36:528\u2013544e510. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.005","journal-title":"Cancer Cell"},{"key":"4323_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.neo.2021.06.007","volume":"23","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhou L, Safran H, Borsuk R, Lulla R, Tapinos N, Seyhan AA, El-Deiry WS (2021) EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201\/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia 23:792\u2013810. https:\/\/doi.org\/10.1016\/j.neo.2021.06.007","journal-title":"Neoplasia"},{"key":"4323_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23:493\u2013500. https:\/\/doi.org\/10.1038\/nm.4296","journal-title":"Nat Med"},{"key":"4323_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153\u2013166. https:\/\/doi.org\/10.1038\/nrc2602","journal-title":"Nat Rev Cancer"},{"key":"4323_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood\u2013brain barrier: bottleneck in brain drug development. NeuroRx 2:3\u201314. https:\/\/doi.org\/10.1602\/neurorx.2.1.3","journal-title":"NeuroRx"},{"key":"4323_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","volume":"140","author":"JW Taylor","year":"2018","unstructured":"Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M (2018) Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neuro Oncol 140:477\u2013483. https:\/\/doi.org\/10.1007\/s11060-018-2977-3","journal-title":"J Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04323-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04323-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04323-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T05:12:34Z","timestamp":1685509954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04323-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04323-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2668091\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"8 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the human research ethics committee of Beijing Tiantan Hospital. The written informed consent was obtained from the subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}